Selective ET(A) receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure

Cardiovascular Research

Volumn 39, Issue 3, 1998, Pages 600-608

  Mulder, Paul ^a   Richard, Vincent ^a   Bouchart, François ^b   Derumeaux, Geneviève ^b   Münter, Klaus ^c   Thuillez, Christian ^a  

^a EA 2656 GRAM   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c Knoll AG   (Germany)

Author keywords

Cardiac remodeling; Echocardiography; ET blockade; Heart failure; Rat

Indexed keywords

4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; SARAFOTOXIN S6C; UNCLASSIFIED DRUG; COLLAGEN; ENDOTHELIN RECEPTOR; PHENYLPROPIONIC ACID DERIVATIVE; PYRIMIDINE DERIVATIVE; SARAFOTOXINS S6; VASOCONSTRICTOR AGENT; VIPER VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; HEART FAILURE; HEART LEFT VENTRICLE MUSCLE; HEART LEFT VENTRICLE PERFORMANCE; HEART RATE; HEART VENTRICLE REMODELING; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SYSTOLIC BLOOD PRESSURE; ANIMAL; BLOOD PRESSURE; CONGESTIVE HEART FAILURE; CORONARY BLOOD VESSEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART MUSCLE; HEART OUTPUT; HEMODYNAMICS; LIGATION; METABOLISM; ORGAN SIZE; PATHOLOGY; WISTAR RAT;

ANIMALS; BLOOD PRESSURE; CARDIAC OUTPUT; COLLAGEN; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; ENDOTHELIN-1; HEART FAILURE, CONGESTIVE; HEART RATE; HEMODYNAMIC PROCESSES; LIGATION; MALE; MYOCARDIUM; ORGAN SIZE; PHENYLPROPIONATES; PYRIMIDINES; RATS; RATS, WISTAR; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; VASOCONSTRICTOR AGENTS; VENTRICULAR REMODELING; VIPER VENOMS;

EID: 0032148267     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00159-X     Document Type: Article

References (43)

1. Gaudron P., Eilles C., Kugler I., Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation. 87:1993;755-763.
2. Gaudron P., Blumrich M., Ertl G. Aggravation of left ventricular dilatation and reduction of survival by a calcium channel blocker in rats with chronic myocardial infarction. Am Heart J. 125:1993;1226-1233.
3. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation. 91:1990;1161-1172.
4. White H.D., Norris R.M., Brown M.A. Left ventricular end-systolic volume as major determinant of survival after recovery from myocardial infarction. Circulation. 76:1987;44-51.
5. SAVE. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-677.
6. Trandolapril Cardiac Evaluation (TRACE) Study. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-1676.
7. Gaudron P., Kugler I., Hu K., Eilles C., Ertl G. Quinapril, initiated after advanced ventricular dilation in patients with chronic infarction, prevents progressive remodeling (Abstract). J Am Coll Cardiol. 27:1996;228A.
8. Pfeffer M.A., Pfeffer J.M., Steinberg C., Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circ Res. 72:1985;406-412.
9. Pfeffer J.M., Pfeffer M.A., Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res. 57:1985;84-95.
10. Cavero P.G., Miller W.L., Heublein D.M., Margulies K.B., Burnett J.C. Jr. Endothelin in experimental congestive heart failure in the anesthetized dog. Am J Physiol. 259:1990;F312-F317.
11. Margulies K.B., Hildebrand F.L. Jr., Lerman A., Perrella M.A., Burnett J.C. Jr. Increased endothelin in experimental heart failure. Circulation. 82:1990;2226-2230.
12. Cody R.J., Haas G.J., Binkley P.F., Capers Q., Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 85:1992;504-509.
13. Cody R.J. The potential role of endothelin as a vasoconstrictor substance in congestive heart failure. Eur Heart J. 13:1992;1573-1578.
14. Wei C.M., Lerman A., Rodeheffer R.J. Endothelin in human congestive heart failure. Circulation. 89:1994;1580-1586.
15. Omland T., Lie R.T., Aakvaag A., Aarsland T., Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 89:1994;1573-1579.
16. Mulder P., Richard V., Derumeaux G. Role of endogenous endothelin in chronic heart failure: effect of a long term treatment with an endothelin antagonist on survival, hemodynamics and cardiac remodeling. Circulation. 96:1997;1976-1982.
17. Teerlink J.R., Löffler B.M., Hess P. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist. Circulation. 90:1994;2510-2518.
18. B receptor mediates both vasodilatation and vasoconstriction in vivo. Biochem Biophys Res Commun. 186:1992;867-873.
19. Guarda E., Katwa L.C., Myers P.R., Tyagi S.C., Weber K.T. Effects of endothelin on collagen turnover in cardiac fibroblasts. Cardiovasc Res. 27:1993;2130-2134.
20. Rasmussen T.E., Jougasaki M., Supaporn T.et al. Cardiovascular actions of ET-B activation in vivo and modulation by receptor antagonism. Am J Physiol. 274:1998;R131-R138.
21. Spinale F.G., Walker J.D., Mukherjee R.et al. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function. Circulation. 95:1997;1918-1928.
22. Sakai S., Miyauchi T., Kobayashi M.et al. Inhibition of myocardial endothelin pathway improves long term survival in heart failure. Nature. 384:1996;353-355.
23. Pfeffer J.M., Finn P.V., Pfeffer M.A. Endothelin-A receptor antagonism in rats with myocardial infarction and failure (Abstract). J Am Coll Cardiol. 29 (suppl A):1997;399A.
24. Selye H., Bajusz E., Grasso S., Mendell P. Simple techniques for surgical occlusion of coronary vessels in the rat. Angiology. 11:1960;398-407.
25. Litwin S.E., Katz S.E., Morgan J.P., Douglas P.S. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation. 89:1994;345-354.
26. Sahn D.J., DeMaria A., Kisslo J., Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 58:1978;1072-1083.
27. Mulder P., Elfertak L., Richard V.et al. Peripheral artery structure and endothelial function in heart failure. Effect of ACE inhibition. Am J Physiol. 271:1996;H469-H477.
28. Mulder P., Devaux B., Richard V.et al. Early vs delayed angiotensin converting enzyme inhibition in experimental chronic heart failure: effects on survival, hemodynamics and cardiovascular remodeling. Circulation. 95:1997;1314-1319.
29. Weber K.T., Janicki J.S., Schroff S.G.et al. Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res. 62:1988;757-765.
30. Nicoletti A., Heudes D., Hinglais N.et al. Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. Hypertension. 26:1995;101-111.
31. Kiowski W., Sutsch G., Hunziker P.et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
32. Ishikawa T., Yanagisawa M., Kimura S., Goto K., Masaki T. Positive chronotropic effects of endothelin, a novel endothelium-derived vasoconstrictor peptide. Pflug Arch Eur J Physiol. 413:1988;108-110.
33. Boudoulas H., Rittgers S.E., Lewis R.P., Leier V.C., Weissler A.M. Changes in diastolic time with various pharmacological agents: implications for myocardial perfusion. Circulation. 60:1979;164-169.
34. Litwin S.E., Grossman W. Diastolic dysfunction as a cause of heart failure. J Am Coll Cardiol. 22:1993;49A-55A.
35. Guth B.D., Heusch G., Seitelberger R., Ross J. Jr. Mechanism of beneficial effect of β-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res. 60:1987;738-746.
36. Andersson B., Lomsky M., Waagstein F. The link between acute haemodynamic adrenergic beta-blockade and long-term effects in patients with heart failure. A study on diastolic function, heart rate and myocardial metabolism following intravenous metoprolol. Eur Heart J. 14:1993;1375-1385.
37. Kjekshus J. Heart rate reduction - a mechanism of benefit? Eur Heart J. 8(suppl):1987;115-122.
38. Frishman W.H., Gabor R., Pepine C., Cavusoglu E. Heart rate reduction in the treatment of chronic stable angina pectoris: experience with a sinus node inhibitor. Am Heart J. 131:1996;204-210.
39. Sakai S., Miyauchi T., Sakurai T.et al. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation. 93:1996;1214-1222.
40. Kelly R.A., Eid H., Kramer B.K.et al. Endothelin enhances the contractile responsiveness of adult rat ventricular myocytes to calcium by a pertussis-toxin sensitive pathway. J Clin Invest. 86:1990;1165-1171.
41. Shubeita H.E., McDonough P.M., Harris A.N.et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes: a paracrine mechanism for myocardial cell hypertrophy. J Biol Chem. 265:1990;20555-20562.
42. Ito H., Hirata Y., Adachi S.et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest. 92:1993;398-403.
43. A receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation. 94:1996;2131-2137.